

**PROMYELCOYTIC LEUKAMIA: MRD
DETECTION & ITS CORRELATION WITH
CLINICAL OUTCOME**

Thesis

*Submitted For fulfillment of the M.D. Degree in Clinical
pathology and Oncologic Laboratory Medicine*

By

Eman Mohammed Abdel Aziz Gafaar
(M.B.B.Ch.M.Sc.)

Supervisors

Prof. Dr. Farida Gad Alla

*Professor of Clinical Pathology
NCI, Cairo University*

Dr. Thoraya M. Abd Elhamid

*Assistant Professor of Medicine
NCI, Cairo University*

Dr. Heba Raslan

*Fellow of Medicine
NCI, Cairo University*

NCI
Cairo University
2009



RECOMMENDATION

- The use of real time RT-PCR routinely in all cases of acute promyelocytic leukemia at diagnosis and follow up to quantify PML/RAR α gene and determine MRD.
 - Follow up treated cases every 3 months to detect early molecular relapse.
 - Using PML-RAR α NCN instead of absolute number of transcripts which enables standardization and avoiding differences among laboratories.
 - To monitor response to treatment by estimating log reduction in PML-RAR α ratio which gives better idea about the efficacy of treatment.
-

Abstract

The aim of the present work is to study the PML-RAR α fusion gene by real-time RT-PCR to quantify the amount of the gene before and after therapy in a trial to assess its prognostic value by monitoring MNRD to improve therapeutic strategies and decision making.

This study carried out on 30 patients at medical oncology department in National Cancer Institute, they were subjected to the following:

At diagnosis: Complete haemogram/BM aspirates examination/Immunophenotyping of myeloid cells using flow cytometric analysis.

Cytochemistry staining/Cytogenetic investigation and FISH whenever indicated/Real time RT-PCR.

After complete remission: Complete haemogram/ BM aspirates examination/FISH whenever indicated.

After consolidation: Complete haemogram/ BM aspirates examination/Real time RT-PCR.

Our study revealed the following:

- All 30 patients achieved HR and six of the relapsed.
- There was a statistically significant difference between hematological parameters before and after therapy.
- Real time PCR for PML-RAR α showed a statistically significant difference between transcripts NCN before and after therapy with marked reduction in PML-RAR α after therapy.

- Monitoring patients at short time points (3 months) is valuable and essential for decision making and choice of proper therapy for patients.
- Patients was divided into 2 groups according to level of NCN those with NCN <10 showed higher DFS and OS and those with NCN ≥ 10 showed shorter DFS.
- Group of patients with 2 or more log reduction had higher DFS.
- Age < 30 years and initial TLC < $10 \times 10^9/L$ were the only prognostic parameter which could predict higher DFS.

Finally real time RT-PCR is excellent method for detection of minimal residual disease for patients of acute promyelocytic leukemia.

Key words: MRD- PML-RAR α - RT-PCR- APL.

**سرطان الدم الميلودي (3) : أكتشافه الجزء المتبقى من
المرض وعلاقته بالحالة الأكلينيكية للمريض**

رسالة مقدمة من

الطبيبة/ إيمان محمد عبد العزيز جعفر

توطئه للحصول على درجة الدكتوراه في الباثولوجيا الإكلينيكية

تحت إشراف

أ.د/ فريدة جاد الله

أستاذ الباثولوجيا الإكلينيكية
المعهد القومي للأورام

د/ ثريا محمد عبد الحميد

أستاذ مساعد الأمراض الباطنة
المعهد القومي للأورام

د/ هبه رسلان

مدرس الباثولوجيا الإكلينيكية
المعهد القومي للأورام

2009

Abstract

The aim of the present work is to study the PML-RAR α fusion gene by real-time RT-PCR to quantify the amount of the gene before and after therapy in a trial to assess its prognostic value by monitoring MNRD to improve therapeutic strategies and decision making.

This study carried out on 30 patients at medical oncology department in National Cancer Institute, they were subjected to the following:

At diagnosis: Complete haemogram/BM aspirates examination/ Immunophenotyping of myeloid cells using flow cytometric analysis.

Cytochemistry staining/Cytogenetic investigation and FISH whenever indicated/Real time RT-PCR.

After complete remission: Complete haemogram/ BM aspirates examination/FISH whenever indicated.

After consolidation: Complete haemogram/ BM aspirates examination/Real time RT-PCR.

Our study revealed the following:

- All 30 patients achieved HR and six of the relapsed.
- There was a statistically significant difference between hematological parameters before and after therapy.
- Real time PCR for PML-RAR α showed a statistically significant difference between transcripts NCN before and after therapy with marked reduction in PML-RAR α after therapy.

- Monitoring patients at short time points (3 months) is valuable and essential for decision making and choice of proper therapy for patients.
- Patients was divided into 2 groups according to level of NCN those with NCN <10 showed higher DFS and OS and those with NCN ≥ 10 showed shorter DFS.
- Group of patients with 2 or more log reduction had higher DFS.
- Age < 30 years and initial TLC < $10 \times 10^9/L$ were the only prognostic parameter which could predict higher DFS.

Finally real time RT-PCR is excellent method for detection of minimal residual disease for patients of acute promyelocytic leukemia.

Key words: MRD- PML-RAR α - RT-PCR- APL.

CONTENTS

INTRODUCTION & AIM OF WORK	1
REVIEW OF LITERATURE	3
APL ○	5
-.....	5
-Molecular basis of APL	7
-Treatment of APL	8
-Genetic diagnosis of APL	10
-Real time PCR	12
-MRD	17
PATIENTS & METHODS	19
STATISTICAL ANALYSIS	22
RESULTS	27
DISCUSSION	35
SUMMARY & CONCLUSION	38
REFERENCES	41
APPENDIX	52
ARABIC SUMMARY	55

LIST OF FIGURES

Figure No.	Description	Page No.
1	Schematic representation of the RAR α gene.	
2	Retinoic acid induces release of the corepressor complex from RXR/ RAR α .	
3	Schematic representation of the PML gene with different PML-RAR α breakpoints.	
4	Schematic representation of the normal activity of the RAR α and PML proteins.	
5	Schematic representation of the role of ATRA in release corepressor complex.	
6	The taq Man assay.	
7	Molecular beacons assay.	
8	Mean age of relapsed and non-relapsed subgroups.	
9	Mean Hb concentration of relapsed and non-relapsed subgroups.	
10	Median platelet count of relapsed and non-relapsed subgroups.	
11	Median NCN at diagnosis of relapsed and non-relapsed subgroups.	
12	Correlation between platelet count and NCN at diagnosis.	
13	Relation between log reduction and DFS.	
14	Effect of NCN upon DFS.	
15	Effect of Log reduction upon over all survival .	

16	Relation of OS and MRD level (NCNmethod)	
17	Disease free survival and its relation to age.	
18	Relation between disease free survival and sex.	
19	Relation between disease free survival and TLC at diagnosis.	
20	Relation between disease free survival and platelets at Diagnosis.	
21	Impact of age upon over all survival.	
22	Relation between over all survival and sex.	
23	Relation between over all survival and platelets at diagnosis.	
24	Relation between over all survival and TLC at diagnosis.	
25	Real time PCR run protocol	
26	PML/RAR α standard curve	
27	Real time PCR hole run of PML/RAR α	
28	Real time PCR cases of APL.	
29	Real time PCR cases of APL .	
30	Real time PCR cases of APL .	

LIST OF TABLES

Table No.	Description	Page No.
1	Age and sex distribution among 30 studied patients.	
2	Hematological parameters of the studied group at presentation.	
3	Haematological parameters in APL patients before and after treatment.	
4	Results of monitoring of PML/RAR α by RT-PCR before and after treatment in APL.	
5	Comparison between relapsed and non relapsed APL patient as regard haemetological parameters at presentation.	
6	Comparison between relapsed and not as regard RT-PCR at diagnosis.	
7	Comparison between relapsed and non as regard RQ-PCR after treatment.	
8	Correlation study between PML-RAR and hameatological parameter in APL patients before treatment.	
9	DFS of the whole studied patients.	
10	Relation of DFS and Log reduction after treatment.	
11	Relation between DFS and MRD level (NCNmethod) after treatment.	
12	Probabilities of DFS according to levels of PML-RARA (after treatment)	

13	Over all survival of the whole studied patients.	
14	Effect of Log reduction upon over all survival.	
15	Relation of OS and MRD level (NCNmethod)	
16	Relation of OS and levels of PML-RAR α number of transcript (after treatment).	
17	Correlation between clinical and biological characteristics at diagnosis and DFS and over all survival.	

ABBREVIATION

ABL	: Abelson
ACT	: autologous stem cell transplantation.
AML	: acute myeloid leukemia.
APL	: acute promyelocytic leukemia.
ATRA	: all-trans retinoic acid.
B2M	: Beta 2 macroglobulin.
BCR	: breakpoint cluster region.
BM	: bone marrow.
BMT	: bone marrow transplantation.
CBP	: CREB binding protein.
CCD	: computer-controlled cooled .
CD	: clusters of differentiation.
CG	:Control gene.
c-DNA	:complementary DNA.
Cp45	: cytochrome p45.
GPX	: gluta thione peroxidase.
CR	: complete remission.
CRABP	: cellular retinoid acid binding protein.
CREB	: cyclic AMP response element binding protein.

CT : Combinations chemotherapy

C_t : threshold cycle.

CTQ : threshold cycle.

DFs : Disease free survival.

DFS : disease free survival.

DIC : disseminated intravascular coagulation.

DNA : deoxy ribonucleic acid.

Ds-DNA :doublestranded DNA.

EAC : Europeaian against cancer.

FAB : French –American-British

FAM : 6-carboxy fluorescein.

FG : fusion gene.

FISH : fuorescence in situ hybridization.

FRET : fluorescence resonance energy transfer.

G6PD : glucose -6-phosphate dehydrogenase.

GAPDH : glyceraldehydes -3- phosphate dehydrogenase.

G-CSH : Granlocyte colony-stimulating factor

GST : Glutathrin stranoferase.

GUS : Beta glucouonidase.

GVH : graft versus host.

HAT : Histone acetytrandferase.

HDAC : Histone deacety lase.

HKGs : House keeping gene.

MRD : minimal residual disease.

NB : Nuclear body.

NCI : national cancer institute.

N-COR : nuclear receptor co repressor.

NK : Natural killer.

NPM : nucleophsmin.

NR : nuclear receptor.

Numa : nuclear matrix-associated gene.

PLZF : promyelocytic leukemia zinc finger.

PML : promyelocytic leukemia.

POZ : Pox virus and zinc finger.

RAR : Retinoid acid receptor.

RARA : retinoic acid receptor α .

RAS : Retinoid acid syndrome.

REF : Ret finger protein.

RQ-PCR : real time quantitative PCR.

Rt-PCR : reverse transcriptase chain reaction.

RXR : Retinoid x receptor.

SCT : stemcell transplantation.

SMRT : silencing mediator for RAR α and thyroid hormone .

SRC : steroid receptor co activator .

t : translocation.

TAMARA : 6-carboxy-tetramethyle rhodamine.

Taq : thermos aquaticus.

TET : tetrachloro-carboxy fluorescin.